Protocol for generation and engineering of thyroid cell lineages using CRISPR-Cas9 editing to recapitulate thyroid cancer histotype progression.
Thyroid carcinoma represents the first malignancy among the endocrine organs.
APA
Pantina VD, Verona F, et al. (2024). Protocol for generation and engineering of thyroid cell lineages using CRISPR-Cas9 editing to recapitulate thyroid cancer histotype progression.. STAR protocols, 5(3), 103263. https://doi.org/10.1016/j.xpro.2024.103263
MLA
Pantina VD, et al.. "Protocol for generation and engineering of thyroid cell lineages using CRISPR-Cas9 editing to recapitulate thyroid cancer histotype progression.." STAR protocols, vol. 5, no. 3, 2024, pp. 103263.
PMID
39128010
Abstract
Thyroid carcinoma represents the first malignancy among the endocrine organs. Investigating the cellular hierarchy and the mechanisms underlying the initiation of thyroid carcinoma is crucial in thyroid cancer research. Here, we present a protocol for deriving thyroid cell lineage from human embryonic stem cells. We also describe steps for engineering thyroid progenitor cells utilizing CRISPR-Cas9 technology, which can be used to perform in vivo studies, thus facilitating the development of representative thyroid tumorigenesis models. For complete details on the use and execution of this protocol, please refer to Veschi et al..
MeSH Terms
Humans; CRISPR-Cas Systems; Thyroid Neoplasms; Gene Editing; Thyroid Gland; Cell Lineage; Human Embryonic Stem Cells; Disease Progression